A CLINICAL RESEARCH CAREER WORKING SPONSOR-SIDE, CRO-SIDE TO SITE-SIDE AT PARATUS CLINICAL
With
Megan Morrison,
Chief Executive Officer
Paratus Clinical
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | December 2025
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
Megan Morrison as the Chief Executive Officer of Paratus Clinical, brings more than 24 years of experience in the clinical research industry. She has held senior leadership roles across sponsor organisations, CROs and clinical sites, giving her a uniquely comprehensive perspective on the challenges and opportunities across the drug development ecosystem.
With a background in pharmacology and a Master of Business Administration, Megan combines scientific expertise with commercial and operational acumen. She is committed to advancing Australia’s role in global clinical research by expanding access to innovative studies, strengthening partnerships with sponsors, and ensuring that high-quality outcomes are delivered for both patients and partners.
In this interview with Australian Health Journal she talks about her career journey, current trends in the industry as well as recent projects. Megan also shares her career advice on being curious, in a frequently changing environment such as clinical research, for the benefit of sponsors getting new therapies to market.
Source: Adapted from Paratus Clinical media releases and website
-
Supporting women in arthroplasty, surgery & orthopaedic oncology
Associate Professor Claudia Di Bella is an academic orthopaedic surgeon based in Melbourne, specialising in orthopaedic oncology and complex joint reconstruction. Originally trained at the world-renowned Rizzoli Orthopaedic Institute (Istituto Ortopedico Rizzoli) in Bologna, Italy, she moved to Australia in 2010 and was awarded Fellowship of the Royal Australasian College of Surgeons in 2013.
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
